Cohen's Corner: Techs deserve a closer look

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.

In this episode of the podcast, Shawn and Jesse discuss how every situation has a solution and the best way to find it.